We provide our clients with pharmacology studies that meet SMC quality and data that can be directly corelated to the results of clinical trials.
SMC quality consists of the following five items.
Model suitability (linking the model to clinical conditions)
SMC Laboratories have supported over 1,000 clients worldwide.
Number of clients
Region
CRO specialized in MASH/NASH-HCC
We can evaluate, analyze, and propose fibrosis, based on our extensive experience.
International Patent Number: WO2011/013247 Title of the invention: "Steatohepatitis-Liver Cancer Model Animal"
Patent number: 2009-178143 Title of invention: Steatohepatitis-liver cancer model animal
Galectin Therapeutics, Inc. (NASDAQ: GALT) conducted a pharmacology study targeting fibrosis using STAM™ mice.
A phase 2b trial was conducted in NASH cirrhosis.
Our area of responsibility
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) conducted a pharmacology study targeting NASH using the STAM™ model. Phase 2 trials targeting liver fibrosis stage NASH are underway.
Our area of responsibility